Akoya Biosciences (AKYA) said Tuesday that it has signed an exclusive global license agreement with NeraCare to develop and commercialize the Immunoprint test on Akoya's multiplexed immunofluorescent platform.
The agreement grants Akoya rights to develop and market the test for clinical research, diagnostic development, or patient testing following regulatory approval, Akoya said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.